A first human foothold for cellular reprogramming

# A first human foothold for cellular reprogramming OCTOBER 11, 2026 A gene therapy designed to turn back the clock on aging cells has now been given to people, and in the first three patients it was well tolerated. For a field built around the possibility of restoring function, the first human observations carry particular weight. They also demand proportion: three participants and eight weeks can open a question, but cannot settle it. Life Biosciences announced the interim results on October 8, 2026, from its Phase 1 trial of a therapy called ER-100. The three participants all have open-angle glaucoma, a chronic disease in which the optic nerve is damaged. It is a leading cause of blindness in older adults. According to the company, vision lost to glaucoma is often considered irreversible, because the nerve cells involved, called retinal ganglion cells, do not naturally regenerate. ER-100 takes an unusual approach. It delivers three genes known as OCT4, SOX2 and KLF4, together called OSK. According to the company, these are used to reset the patterns of gene activity in a cell and return it to a more youthful, functional state. The company calls this epigenetic restoration. In plain terms, the idea is to change which genes are switched on, rather than to fix a single faulty gene. Each participant received one injection into the eye. They also took the antibiotic doxycycline by mouth every day for 56 days. The doxycycline acts as a switch that turns the OSK genes on. A course of oral steroid, tapered down over time, was given to limit inflammation from the immune response to the virus used to deliver the genes. On safety, the company reports no dose-limiting toxicities, no serious adverse events and no adverse events of special interest through Day 56. All side effects that were reported were linked to the injection procedure, the steroid or conditions the patients already had, according to Life Bio. That attribution comes from the company, not an independent review. The trial's Data Safety Monitoring Board recommended moving to a higher dose, about three times the first one. The vision results are the part that draws attention. Two of the three participants improved on the Humphrey visual field test, a standard exam that measures how well a person detects light across many points in their field of vision. In each of those two, at least 28% of test points improved by more than 4 decibels. The company called these observations preliminary and encouraging. Here is why caution matters, and this is where the argument is weakest. Three patients is a very small group. The trial is open-label, meaning everyone knew they were receiving the treatment. The company's materials do not describe a comparison group, so we cannot tell whether the gains exceed what would be expected without treatment. Follow-up so far is only 56 days. Visual field tests can vary from one session to the next, so it is not possible to say whether the gains came from the therapy. The company itself notes that this phase of the study is designed to evaluate safety and tolerability. ER-100 is investigational, and the company's materials describe it as being evaluated in the trial, registered as NCT07290244. Please do not start, stop or change any glaucoma treatment, or any medication, including antibiotics such as doxycycline or steroids, on the basis of this report; talk to your own clinician first. Phase 1 trials are the first step, and as a general rule, later and larger studies would be needed to show that a therapy works and remains safe over longer periods. That means any approved treatment, if one ever emerges, is likely years away, though that is our judgment rather than something the company has stated. Still, the result matters for a broader reason. It is early human evidence that a controlled version of this cell-reprogramming approach can be given to patients without obvious serious harm at the starting dose. The company says it hopes the method can eventually address other age-related diseases, but that remains unproven. WHAT TO WATCH NEXT Results from the higher-dose group, longer follow-up in the first three patients, and whether the trial's planned inclusion of patients with another optic nerve condition, NAION, produces data of its own. The next advance will be more follow-up, more participants, and a clearer account of what changed. That is how an extraordinary possibility becomes something medicine can judge. Source: Life Biosciences (press release; also reported by STAT) Life Biosciences (press release; also reported by STAT): https://www.lifebiosciences.com/life-biosciences-announces-first-in-human-data-from-ongoing-phase-1-trial-evaluating-er-100-in-optic-neuropathies/ ---